Additionally, the mutational status of melanoma patients bearing BM did not apparently influence OS, although a positive trend was seen in BRAF-mutated patients treated with immunotherapy (14.2 months) as compared to those treated with targeted therapy alone (8.8 months).
← all excerpts
An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival.
1
—
—